Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging therapeutic strategies in muscular dystrophy: an updated review on pathogenesis and treatment advances.

Molecular biology reports - 12 Jan 2026

Parwez Shahid, Ahmad Khurshid, Lee Eun Ju, Choi Inho

Abstract excerpt

Muscular dystrophy (MD) comprises a class of genetic conditions characterized by the progressive degeneration and weakness of skeletal muscle. Genetic etiologies differ among the major muscular dystrophies: myotonic dystrophy type 1 (DM1) is linked to CTG repeat expansion in DMPK whereas DM2 is linked to CCTG repeat expansion in CNBP; facioscapulohumeral muscular dystrophy (FSHD1) is linked to contraction of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DMPK gene
Share to Genetic Therapy
Share to Muscular Dystrophies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Muscular Dystrophy, Facioscapulohumeral

Share to Mutation

Share to Myotonic Dystrophy

Source

Identifiers

PMID: 41524923
DOI: 10.1007/s11033-025-11418-x

Genes

DUX4
CNBP
DMPK
SMCHD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging therapeutic strategies in muscular dystrophy: an updated review on pathogenesis and treatment advances.PMID 41524923Read ↗

Towards a Cure: Emerging Therapeutic Advances for DMD, LGMD, and GNEM- Insights from Pre-Clinical and Clinical ResearchSemantic proximity Read ↗

Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular MechanismSemantic proximity Read ↗

An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Duchenne muscular dystrophy: an updated review of common available therapiesSemantic proximity Read ↗

Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.Semantic proximity Read ↗

Drug development progress in duchenne muscular dystrophySemantic proximity Read ↗

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible TreatmentsSemantic proximity Read ↗

Therapeutic approaches for Duchenne muscular dystrophy.Semantic proximity Read ↗

Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular DystrophySemantic proximity Read ↗

Facioscapulohumeral Muscular Dystrophy.Semantic proximity Read ↗

Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments.Semantic proximity Read ↗

Duchenne muscular dystrophy: from gene to gene-ius therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.